These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 31219754)
1. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice. Zhou C; Lehar S; Gutierrez J; Rosenberger CM; Ljumanovic N; Dinoso J; Koppada N; Hong K; Baruch A; Carrasco-Triguero M; Saad O; Mariathasan S; Kamath AV MAbs; 2016; 8(8):1612-1619. PubMed ID: 27653831 [TBL] [Abstract][Full Text] [Related]
3. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model. Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725 [TBL] [Abstract][Full Text] [Related]
4. Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti- Cai H; Yip V; Lee MV; Wong S; Saad O; Ma S; Ljumanovic N; Khojasteh SC; Kamath AV; Shen BQ Drug Metab Dispos; 2020 Nov; 48(11):1161-1168. PubMed ID: 32839277 [TBL] [Abstract][Full Text] [Related]
5. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Peck M; Rothenberg ME; Deng R; Lewin-Koh N; She G; Kamath AV; Carrasco-Triguero M; Saad O; Castro A; Teufel L; Dickerson DS; Leonardelli M; Tavel JA Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910894 [No Abstract] [Full Text] [Related]
6. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517 [TBL] [Abstract][Full Text] [Related]
7. Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections. Stagg NJ; Katavolos P; Achilles Poon K; Zhong S; Ljumanovic N; Kamath A; Cai H; Carrasco-Triguero M; Halpern W Toxicol Appl Pharmacol; 2022 Jan; 435():115811. PubMed ID: 34896194 [TBL] [Abstract][Full Text] [Related]
8. Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data. Li C; Zhang C; Deng R; Leipold D; Li D; Latifi B; Gao Y; Zhang C; Li Z; Miles D; Chen SC; Samineni D; Wang B; Agarwal P; Lu D; Prabhu S; Girish S; Kamath AV Clin Transl Sci; 2019 Sep; 12(5):534-544. PubMed ID: 31115997 [TBL] [Abstract][Full Text] [Related]
9. Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging. Zhou C; Cai H; Baruch A; Lewin-Koh N; Yang M; Guo F; Xu D; Deng R; Hazenbos W; Kamath AV PLoS One; 2019; 14(10):e0224096. PubMed ID: 31661493 [TBL] [Abstract][Full Text] [Related]
10. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715 [TBL] [Abstract][Full Text] [Related]
11. Anti-Lymphocyte Antigen 6 Complex, Locus E- Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064 [TBL] [Abstract][Full Text] [Related]
12. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC. Figueroa I; Leipold D; Leong S; Zheng B; Triguero-Carrasco M; Fourie-O'Donohue A; Kozak KR; Xu K; Schutten M; Wang H; Polson AG; Kamath AV MAbs; 2018 Jul; 10(5):738-750. PubMed ID: 29757698 [TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. Leipold DD; Figueroa I; Masih S; Latifi B; Yip V; Shen BQ; Dere RC; Carrasco-Triguero M; Lee MV; Saad OM; Liu L; He J; Su D; Xu K; Vuillemenot BR; Laing ST; Schutten M; Kozak KR; Zheng B; Polson AG; Kamath AV MAbs; 2018; 10(8):1312-1321. PubMed ID: 30183491 [TBL] [Abstract][Full Text] [Related]
14. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881 [TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates. Yang C; Zhao X; Sun X; Li J; Wang W; Zhang L; Gou S Xenobiotica; 2019 Sep; 49(9):1097-1105. PubMed ID: 30299189 [TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Wang H; Rangan VS; Sung MC; Passmore D; Kempe T; Wang X; Thevanayagam L; Pan C; Rao C; Srinivasan M; Zhang Q; Gangwar S; Deshpande S; Cardarelli P; Marathe P; Yang Z Biopharm Drug Dispos; 2016 Mar; 37(2):93-106. PubMed ID: 25869904 [TBL] [Abstract][Full Text] [Related]
18. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys. Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958 [TBL] [Abstract][Full Text] [Related]
19. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591 [TBL] [Abstract][Full Text] [Related]
20. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass. Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]